Anavex Life Sciences (AVXL) investor relations material

Key clinical and research updates

• Completed Phase 2/3 study in Alzheimer's, with regulatory review ongoing at EMA and plans to engage other regulators.

• Drug demonstrated superior safety and efficacy to approved antibodies, with no deaths and manageable side effects.

• Open-label extension showed long-term benefits, including delayed or halted brain atrophy and significant cognitive improvements.

• Genetic analysis identified sigma-1 and COL24A1 wild type genes as predictors of better response, benefiting up to 70% of patients.

• Additional indications in pipeline include Parkinson's, schizophrenia, rare diseases, and a pain drug.

Mechanism of action and patient impact

• Drug targets upstream autophagy impairment, aiming to restore cellular function before downstream Alzheimer's pathology develops.

• Oral, once-daily administration offers convenience and scalability, reducing logistical and financial burdens for families.

• No need for repeated imaging or invasive procedures, streamlining care for patients and physicians.

• Prevention potential demonstrated in animal studies, suggesting future use in at-risk populations.

• Patient-centric approach supports adherence and accessibility across diverse populations.

Comparative efficacy and commercialization plans

• Drug showed numerically superior cognitive outcomes to Kisunla and Leqembi in ITT analyses.

• Genetic profiling further strengthens efficacy data, with simple tests enabling patient selection.

• Engaging with advocacy groups, KOLs, and commercial entities to determine commercialization strategy.

• Strong IP protection with patents filed for new data, covering portfolio up to 2039.

• Cash position supports operations for over three years, with support from foundations and experienced team.